Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Hepatology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2009.01.017PMID 19447518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early and Accurate Prediction of Peg‐IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells

  2008cited by this paper
• Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C

  2008cited by this paper
• Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin

  2007cited by this paper
• Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C

  2007cited by this paper
• Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

  2007influential reference
• Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy

  2006cited by this paper
• Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C

  2006cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• Diagnosis and treatment of chronic hepatitis C infection

  2006cited by this paper
• International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

  2005cited by this paper
• Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon‐alpha 2a and ribavirin according to virological response

  2005cited by this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• International, Multicenter, Randomized, Controlled Study Comparing Dynamically Individualized Versus Standard Treatment in Patients with Chronic Hepatitis C* , **

  2005cited by this paper
• Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?

  2004cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Living Donor Liver Transplantation in South Asia: Single Center Experience on Intermediate-Term Outcomes

  2018cites this paper
• Impact of rs12979860 polymorphism on liver morphology in chronic HCV infection

  2015cites this paper
• Address of Correspondence

  2014cites this paper
• Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

  2014influential citation
• Prediction of efficacy to pegylated interferon‐α‐2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks

  2014cites this paper
• Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons &agr;-2a and &agr;-2b, plus ribavirin

  2013cites this paper
• Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?

  2013cites this paper
• Effects of triple‐drug therapy with nitazoxanide, high‐dose ribavirin and peginterferon‐α‐2a in patients with chronic hepatitis C

  2013cites this paper
• Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

  2012cites this paper
• Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy☆

  2012cites this paper
• Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference

  2012cites this paper
• Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa‐2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3

  2012cites this paper
• High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials

  2012cites this paper
• Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

  2012cites this paper
• Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

  2012cites this paper
• Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.

  2011cites this paper
• HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.

  2011cites this paper
• How to use virological tools for the optimal management of chronic hepatitis C

  2011cites this paper
• 20. Hepatitis C

  2011cites this paper
• HCV Genetic Elements Determining the Early Response to Peginterferon and Ribavirin Therapy

  2010cites this paper
• Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment

  2010cites this paper
• Treatment of chronic hepatitis C in elderly patients

  2010cites this paper
• Hepatitis C Treatment: current and future perspectives

  2010cites this paper
• Dissertação | Artigo de Revisão Bibliográfica Mestrado Integrado em Medicina ABORDAGEM TERAPÊUTICA DA HEPATITE C CRÓNICA NA POPULAÇÃO ADULTA

  2010cites this paper
• Investigational drugs for hepatitis C

  2010cites this paper
• Treatment of Hepatitis C in the Pre-DAA's Era: Treat Now or Wait for New Medications?

  2010cites this paper
• What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?

  2009cites this paper
• New therapies for hepatitis C virus infection.

  2009cites this paper
• Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?

  2009cites this paper
• Review article: novel therapeutic options for chronic hepatitis C

  2008cites this paper